{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreie46vdevqiqxjdv52vahrp7tjzfxamq46edraesbfipmhhf6jwkdm",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mf4lnjqph4f2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/02/17/india-ireland-china-glp-lilly-novo-obesity-vaccines-peanuts-africa/?utm_campaign=rss",
  "publishedAt": "2026-02-17T14:21:26.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "The FDA rejected a Disc Medicine therapy for a rare blood disorder, the first experimental drug to go through a new program to fast-track drug reviews",
  "title": "STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more",
  "updatedAt": "2026-02-17T14:21:30.000Z"
}